Clinical Trials Logo
  1. Home
  2. Central Retinal Vein Occlusion
  3. NCT00383773
  4. Details
NCT00383773 Clinical Trial

Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion

Central Retinal Vein Occlusion Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT00383773
Other study ID # 1yumbo-HMO-CTIL
Secondary ID
Status Not yet recruiting
Phase N/A
First received October 3, 2006
Last updated October 3, 2006
Start date October 2006
Est. completion date October 2007

Study information
Verified date September 2006
Source Hadassah Medical Organization
Contact Michael Halpert, MD.
Phone 00972507874385
Email halpert@cc.huji.ac.il
Is FDA regulated No
Health authority Israel: Israeli Health Ministry Pharmaceutical Administration
Study type Interventional

Clinical Trial Summary

Patients with Central Retinal Vein Occlusion will undergo vitrectomy, a small needle of about 71 micron will enter a branch retinal vein and TPA will be injected into the obstracted vein.

Description:

Patients with Central Retinal Vein Occlusion less than 6 month duration and reduction of vision to 6/21 will go OCT and FANG examinations.

Patient will be operated vitrectomy, and a branch retinal vein will be punctured by small needle and rTPA 200mcg/ml will be injected to the vein.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 10
Est. completion date October 2007
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- crvo less than 6 month

- Visual Acuity less than 6/21

- No prior eye surgery except cataract.

Exclusion Criteria:

- Retinal/iris neovascularization

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Procedure:
• Retinal endo vascular surgery

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Hadassah Medical Organization

Outcome
Type Measure Description Time frame Safety issue
Primary Visual acuity
Primary Amount of macular edema.
See also
  Status Clinical Trial Phase
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT01969708 - Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Phase 3
Completed NCT01231633 - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) N/A
Terminated NCT00969293 - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Phase 1
Completed NCT03981549 - Treatment of Central Retinal Vein Occlusion Using Stem Cells Study Phase 1/Phase 2
Completed NCT02274259 - Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Phase 4
Completed NCT01360385 - Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab N/A
Completed NCT00952614 - A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion N/A
Recruiting NCT04601701 - Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. N/A
Withdrawn NCT03417401 - Surgical Stabilizer Assisted RVC With rtPA for CRVO Phase 1
Completed NCT01976312 - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Phase 3
Completed NCT01724554 - Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion Phase 1/Phase 2
Completed NCT01471691 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Phase 1/Phase 2
Active, not recruiting NCT01011374 - Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion Phase 1
Completed NCT03223714 - Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion Phase 3
Recruiting NCT01827722 - Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Phase 4
Completed NCT00906685 - Bevacizumab for Central Retinal Vein Occlusion Study Phase 3
Active, not recruiting NCT04793100 - Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections N/A
Recruiting NCT02405741 - Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Phase 2
Recruiting NCT01348633 - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye N/A